The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
Lehmann Jochen, Pieper Birgit, Tetrahedron, 3 (1992) N 12, S 1537-1538
作者:Lehmann Jochen, Pieper Birgit
DOI:——
日期:——
Ligand-Directed Covalent Modification of Protein
申请人:Celgene CAR LLC
公开号:US20170218353A1
公开(公告)日:2017-08-03
The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
[EN] LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN<br/>[FR] MODIFICATION COVALENTE DE PROTÉINE, DIRIGÉE SUR UN LIGAND
申请人:AVILA THERAPEUTICS INC
公开号:WO2011082285A1
公开(公告)日:2011-07-07
The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.
Enantioselective synthesis of (R)- and (S)-5-dimethylaminomethyl-4,5-dihydro-2(3H)-furanone methobromide - constrained analogues of acetylcholine
作者:Jochen Lehmann、Birgit Pieper
DOI:10.1016/s0957-4166(00)86054-1
日期:1992.12
S6 and R6 represent constrained analogues of acetylcholine. Two effective routes to synthesize the enantiopure title compounds starting from either D- or L- glutamic acid are reported.